News | December 04, 2007

Cepheid Launches New Tests in Europe for Simultaneous Detection of MRSA

December 5, 2007 - Cepheid said yesterday it released Xpert MRSA/SA-Blood Cultures and Xpert MRSA/SA-Skin and Soft Tissue Infection (SSTI) tests in Europe designed to enable simultaneous rapid detection of two leading causes of hospital and community acquired infections - Methicillin resistant Staphylococcus aureus (MRSA) and Staphylococcus aureus.

The tests work directly from blood cultures and soft tissue infection samples. Both the Xpert MRSA/SA-SSTI and Xpert MRSA/SA-BC products deliver results in about 50 minutes, enabling healthcare professionals to rapidly determine the presence or absence of MRSA and SA with a single test. The company says both products employ a multiplex molecular protocol for potentially avoiding clinical false-positive MRSA results. While SA infections are generally treatable with common antibiotics, MRSA is resistant to numerous penicillin and cephalosporin antibiotics.

"Staphylococcus aureus is a major cause of bloodstream infection, associated with substantial mortality and healthcare cost. Its impact may be more severe in cases of infection caused by methicillin-resistant strains, which are more difficult to treat,” said Professor Marc Struelens of the Catholic University Hospital, Brussels and head of the Belgian Staphylococcal Reference Laboratory. “By analyzing positive blood cultures, we found the Xpert MRSA/SA test to be very reliable for rapid DNA-based detection and identification of S. aureus and MRSA bacteremia.”

The GeneXpert System is a closed, self-contained, fully integrated and automated platform the company says is a shift in the automation of molecular analysis, producing accurate results in a timely manner with minimal risk of contamination. The GeneXpert System is the only system to combine on-board sample preparation with real-time PCR (polymerase chain reaction) amplification and detection functions for fully integrated and automated nucleic acid analysis. The system is designed to purify, concentrate, detect and identify targeted nucleic acid sequences thereby delivering answers directly from unprocessed samples.

For more information: www.cepheid.com

Related Content

pre-operative testing, NYU Langone, guidelines
News | June 09, 2015
Professional physician associations consider certain routine tests before elective surgery to be of low value and high...
News | March 26, 2015
March 26, 2015 — Siemens Healthcare introduced a new angiography system and new cardiac ultrasound apps at the 2015...
Nephrocheck Test System, Blood testing, contrast media

Image courtesy of Astute Medical

News | January 27, 2015
Ortho-Clinical Diagnostics Inc. announced the nationwide availability to hospitals of the Nephrocheck Test System...
blood testing, nephrocheck
News | September 30, 2014
The U.S. Food and Drug Administration has allowed marketing of the NephroCheck test, a first-of-a-kind laboratory test...
News | June 15, 2008
June 16, 2008 - 3M Health Care said today its 3M Rapid Detection Flu A B Test demonstrated better clinical and analyt
News | March 23, 2008
March 24, 2008 – AdvanDx received Frost and Sullivan’s 2008 Technology Innovation of the Year Award in the field of r
News | March 11, 2008
March 12, 2008 - Neoteric Technology Ltd.
News | February 25, 2008
February 26, 2008 - Masimo announced it would debut its technology for noninvasive and continuous total hemoglobin (S
News | February 04, 2008
February 5, 2008 - Patients with diabetes, cardiac problems, kidney disorders or high blood pressure could benefit fr
News | January 13, 2008
January 14, 2008 – A new, hand-held creatinine monitoring system, Nova StatSensor Creatinine, was released last week
Overlay Init